EyePoint Pharmaceuticals EYPT 深 沪
等待开盘 10-03 09:30:00 美东时间
13.50
+0.585
+4.53%
华盛通- 最 高13.75
- 今 开12.92
- 成交量 119.54万股
- 最 低 12.54
- 昨 收 12.915
- 总市值 9.29亿
- 52周最高 14.91
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 3.91
- 委 比 10.35%
- 总股本 6881.17万
- 历史最高 39.40
- 量 比 0.98
- 振 幅 9.37%
- 历史最低 2.19
- 每 手 1
- 风险率 2.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多贝达药业:贝达取得在中国(包括香港、澳门和台湾)区域开发和商业化的EYP-190...
有投资者在深交所互动平台向贝达药业提问："请详细解释一下贵公司和Eyepoint是合作开发模式，当时签订授权协议时的首付款和里程碑以及分成是多少？"公司回复称...
09-11 16:10
EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy
Eyepoint Pharma (($EYPT)) announced an update on their ongoing clinical study. ...
08-16 00:25
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $27 Price Target
Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $27 price target.
08-07 20:52
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
EyePoint Pharmaceuticals Q2 EPS $(0.85) Misses $(0.81) Estimate, Sales $5.333M Miss $6.627M Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.81) by 4.29 percent. This is a 46.55 percent decrease over losses of $(0.58) per
08-06 19:03
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
EyePoint Pharmaceuticals announced that its CEO, Jay S. Duker, M.D., will participate in a fireside chat at the H.C. Wainwright Ophthalmology Virtual Conference on August 13. The event will be webcast live and available for replay on the company's website for 90 days. EyePoint focuses on developing innovative treatments for serious retinal diseases, with its lead candidate, DURAVYU™, in Phase 3 trials for wet AMD and DME. Despite current therapie...
08-06 11:30
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
EyePoint Pharmaceuticals will host a conference call on August 6, 2025, to discuss its second quarter 2025 financial results and recent developments. The company, focused on innovative treatments for serious retinal diseases, is advancing its lead product, DURAVYU™, which is in Phase 3 trials for wet AMD and Phase 2 for DME. The company aims to improve patient lives through its pipeline of innovative therapies.
07-30 11:00
DURAVYU治疗湿性AMD的两项关键性III期临床试验均完成入组
北京时间7月29日，贝达药业战略合作伙伴EyePoint Pharmaceuticals, Inc.（纳斯达克股票代码：EYPT，以下简称“EyePoint”...
07-29 19:47
EyePoint Completes Enrollment for Phase 3 Trials
EyePoint Pharmaceuticals ( ($EYPT) ) just unveiled an update. On July 29, 2025,...
07-29 19:28
